BOCI Securities: Slightly lowers target price of Postal Savings Bank Of China (01658) to 6.62 Hong Kong dollars, maintains "buy" rating.
Postal Savings Bank of China's attributable net profit in the fourth quarter of 2025 increased by 1.7% compared to the same period last year, slightly faster than the growth of 1.2% in the third quarter. The bank believes that this growth was mainly driven by the increase in operating income, the slowing decline in net interest margin, and reduced operating expenses.
released a research report stating that the current stock valuation of Postal Savings Bank Of China (01658) is relatively low, with a price corresponding to a forecasted P/B ratio of 0.48 times in 2026. However, due to its excellent asset quality and stable dividend payout ratio, it should receive a higher P/B ratio valuation. Based on a forecasted P/B ratio of about 0.65 times in 2026, the target price is slightly lowered from HK$6.84 to HK$6.62, while maintaining a "buy" rating.
The net profit attributable to shareholders for the fourth quarter of 2025 of Postal Savings Bank Of China increased by 1.7% year-on-year, slightly faster than the 1.2% growth in the third quarter. The bank believes that this was mainly driven by growth in operating income, a slowdown in the decline of net interest margin, and reduced operating expenses. As a result, the full-year net profit attributable to shareholders increased by 1.1% year-on-year, with operating income also increasing by 1.9% year-on-year. Although the non-performing loan ratio increased in the fourth quarter, it remains at the lowest level among its peers, and the provision coverage ratio is at a high level.
Related Articles

ANALOGUE HLDGS(01977) will forfeit unclaimed 2019 second interim dividend.

The new weight loss drug from LLY.US has been approved by the FDA, marking the entry of the weight loss drug market into the "oral administration era".

Alibaba (09988) releases the strongest domestic programming model Qwen3.6-Plus
ANALOGUE HLDGS(01977) will forfeit unclaimed 2019 second interim dividend.

The new weight loss drug from LLY.US has been approved by the FDA, marking the entry of the weight loss drug market into the "oral administration era".

Alibaba (09988) releases the strongest domestic programming model Qwen3.6-Plus






